What is feasible for one person may be unaffordable for another, said Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor, Midwestern University Chicago College of Pharmacy, who practices at the Northwestern Medicine Infectious Disease Center.
What is feasible for one person may not be affordable for another, even for $10 vs $100, and these are conversations that should start before patients arrive to the pharmacy and are met with possible sticker shock, said Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor at Midwestern University Chicago College of Pharmacy, who practices at the Northwestern Medicine Infectious Disease Center in Chicago.
Transcript
How can we improve access to care for high-risk patients who have trouble affording their antiretroviral therapy or pre-exposure prophylaxis medications?
So this should really be a conversation that starts at the prescriber’s office when the prescription is sent and setting that expectation that if the cost is not feasible, that they need to call right away; like, don’t not pick up the prescription and then come back in 3 months and say, “Oh, it was, you know, I couldn’t afford to pick it up.” And I prefer to use that term feasible because expensive might be $10 for someone vs $100 for someone else. So even if the medication is $10, and they can’t afford it, that’s not feasible for them. So I really like that terminology.
We don’t want anyone to have sticker shock at the pharmacy and just say, “Nope, not getting it,” turn around, come out, maybe not even come back to the doctor’s office because they’re like, “Well, this doctor wants me on a therapy that’s $2500 a month,” when maybe that just needed a prior authorization and they didn’t understand that.
And I think it’s important to normalize the need for patient assistance programs, whether it’s through grants or co-payment assistance or through the manufacturer. The goal for everybody is to get that payment down to zero, regardless of their socioeconomic status.
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More